{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:00:48Z","timestamp":1789826448304,"version":"4.0.1"},"reference-count":47,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Monoclonal gammopathy of undetermined significance (MGUS) is associated with an increased risk of cardiovascular disease. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have demonstrated cardiorenal benefits in patients with type 2 diabetes, but their effectiveness in patients with MGUS remains unexplored.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the effectiveness of GLP-1 RAs for primary prevention of major adverse cardiovascular and cerebrovascular events (MACCE) in patients with MGUS and diabetes.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective cohort study used a propensity score\u2013matched analysis of data from the TriNetX Global Database, encompassing patients diagnosed with diabetes and MGUS between January 1, 2018, and January 13, 2023. Patients with prior heart failure (HF), ischemic heart disease, coronary revascularization, or stroke or transient ischemic attack before MGUS diagnosis were excluded. The cohort was divided into 2 groups: GLP-1 RA users and nonusers at baseline. After 1:1 propensity score matching, GLP-1 RA users and nonusers were compared up to 5 years from the MGUS diagnosis date. Data analyses were completed January 19, 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n GLP-1 RA use within 1 year before MGUS diagnosis.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was MACCE, defined as a composite of all-cause mortality, new-onset HF, acute coronary syndrome, and stroke or transient ischemic attack. Secondary end points included individual MACCE components, decompensated HF, and acute kidney injury or end-stage kidney disease.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 4871 patients with MGUS (mean [SD] age, 68.9 [10.1] years; 2366 [48.5%] male) were included (473 GLP-1 RA users and 4398 non-users). A total of 460 users were matched to 460 nonusers, with balanced characteristics (mean [SD] age, 65.0 [10.6] vs 65.1 [11.0] years; 229 [49.7%] male vs 234 [50.8%] male), including 14 patients (3.0%) vs 13 patients (2.8%) identifying as Asian, 8 (21.3%) vs 92 (20.0%) as Black or African American, 25 patients (5.4%) vs 20 patients (4.3%) as Hispanic or Latino, and 243 patients (52.8%) vs 250 patients (54.3%) as White. GLP-1 RA use was associated with a significantly lower risk of MACCE (hazard ratio [HR], 0.75; 95% CI, 0.60-0.93). Significant reductions were also observed in all-cause mortality (HR, 0.57; 95% CI, 0.37-0.87), new-onset HF (HR, 0.69; 95% CI, 0.54-0.90), decompensated HF (HR, 0.60; 95% CI, 0.43-0.84), and acute kidney injury or end-stage kidney disease (HR, 0.73; 95% CI, 0.57-0.92).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The findings of this cohort study of GLP-1 RA use vs no use in patients with MGUS and diabetes suggest the potential of GLP-1 RA for primary prevention of MACCE. These findings warrant further investigation in prospective randomized trials.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.17541","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T11:00:27Z","timestamp":1751281227000},"page":"e2517541","source":"Crossref","is-referenced-by-count":14,"title":["GLP-1 RA Use and Major Adverse Cardiovascular Events in Patients With Monoclonal Gammopathy of Undetermined Significance"],"prefix":"10.1001","volume":"8","author":[{"given":"Kuan-Yu","family":"Chi","sequence":"first","affiliation":[{"name":"Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmin","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Desphande","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Lun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushri","family":"Soni","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Gonzales-Uribe","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Lessa","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Ashraf","family":"Morgan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chang","sequence":"additional","affiliation":[{"name":"Section of Neurosurgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Shiuan","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Education, Center for Evidence-Based Medicine, Taipei Medical University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zafer","family":"Akman","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Nouri","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raiza","family":"Rossi","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Golsa","family":"Babapour","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Varrias","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri","family":"Parker","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Hematology, Yale University School of Medicine and Yale Cancer Center, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren A.","family":"Baldassarre","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alokkumar","family":"Jha","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Muchtar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C.","family":"Hull","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Kwan","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Nanna","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"issue":"23","key":"zoi250553r1","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1182\/blood.2019846782","article-title":"Monoclonal gammopathy of undetermined significance.","volume":"133","author":"Mouhieddine","year":"2019","journal-title":"Blood"},{"issue":"13","key":"zoi250553r2","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance.","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"key":"zoi250553r3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.bbacli.2016.05.004","article-title":"Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance.","volume":"6","author":"Shimanovsky","year":"2016","journal-title":"BBA Clin"},{"issue":"8","key":"zoi250553r4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.4065\/84.8.685","article-title":"Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients.","volume":"84","author":"Bida","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"zoi250553r5","doi-asserted-by":"publisher","first-page":"854","DOI":"10.3324\/haematol.2011.054015","article-title":"Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study.","volume":"97","author":"Kristinsson","year":"2012","journal-title":"Haematologica"},{"issue":"2","key":"zoi250553r6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1046\/j.1365-2141.2001.02533.x","article-title":"Mortality and causes of death in patients with monoclonal gammopathy of undetermined significance.","volume":"112","author":"Gregersen","year":"2001","journal-title":"Br J Haematol"},{"issue":"5","key":"zoi250553r7","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s12265-019-09950-w","article-title":"MGUS predicts worse prognosis in patients with coronary artery disease.","volume":"13","author":"Xu","year":"2020","journal-title":"J Cardiovasc Transl Res"},{"key":"zoi250553r8","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.3389\/fimmu.2017.01347","article-title":"Pro-inflammatory state in monoclonal gammopathy of undetermined significance and in multiple myeloma is characterized by low sialylation of pathogen-specific and other monoclonal immunoglobulins.","volume":"8","author":"Bosseboeuf","year":"2017","journal-title":"Front Immunol"},{"issue":"3","key":"zoi250553r9","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.ijcard.2011.11.099","article-title":"Osteoprotegerin\/RANK\/RANKL axis and atrial remodeling in mitral valvular patients with atrial fibrillation.","volume":"166","author":"Cao","year":"2013","journal-title":"Int J Cardiol"},{"issue":"2","key":"zoi250553r10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1365-2141.1995.tb03296.x","article-title":"Diagnostic value of serum IL-6 level in monoclonal gammopathies.","volume":"89","author":"DuVillard","year":"1995","journal-title":"Br J Haematol"},{"issue":"4","key":"zoi250553r11","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement.","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"issue":"3","key":"zoi250553r12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jaccao.2022.05.009","article-title":"Cardiovascular morbidity in monoclonal gammopathy of undetermined significance: a Danish nationwide study.","volume":"4","author":"Schwartz","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"10193","key":"zoi250553r13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"24","key":"zoi250553r14","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes.","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi250553r15","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"zoi250553r16","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity.","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi250553r17","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s11606-024-09076-z","article-title":"Association between GLP-1 receptor agonists and incidence of lung cancer in treatment-na\u00efve type 2 diabetes.","volume":"40","author":"Song","year":"2025","journal-title":"J Gen Intern Med"},{"issue":"7","key":"zoi250553r18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes.","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"zoi250553r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115170","article-title":"Glucagon-like peptide-1 agonists reduce cardiovascular events in cancer patients on immune checkpoint inhibitors.","volume":"216","author":"Chiang","year":"2025","journal-title":"Eur J Cancer"},{"key":"zoi250553r20","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaf017","article-title":"Cardiovascular outcomes and mortality in diabetic multiple myeloma patients initiated on proteasome inhibitors according to prior use of glucagon-like peptide 1 agonists.","author":"Chang","year":"2025","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"zoi250553r21","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkae095","article-title":"Association between glucagon-like peptide-1 receptor agonist use and progression of monoclonal gammopathy of uncertain significance to multiple myeloma among patients with diabetes.","volume":"8","author":"Grandhi","year":"2024","journal-title":"J Natl Cancer Inst Cancer Spectr"},{"issue":"2","key":"zoi250553r22","doi-asserted-by":"publisher","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research.","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"issue":"7","key":"zoi250553r23","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1001\/jama.2022.0210","article-title":"Comparison of mRNA-1273 and BNT162b2 vaccines on breakthrough SARS-CoV-2 infections, hospitalizations, and death during the Delta-predominant period.","volume":"327","author":"Wang","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"zoi250553r24","doi-asserted-by":"publisher","first-page":"5912","DOI":"10.1038\/s41467-024-50199-y","article-title":"GLP-1 receptor agonists\u2019 impact on cardio-renal outcomes and mortality in T2D with acute kidney disease.","volume":"15","author":"Pan","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"zoi250553r25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41746-021-00467-8","article-title":"A vital sign-based prediction algorithm for differentiating COVID-19 versus seasonal influenza in hospitalized patients.","volume":"4","author":"Yanamala","year":"2021","journal-title":"NPJ Digit Med"},{"issue":"8","key":"zoi250553r26","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S1470-2045(24)00278-X","article-title":"Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study.","volume":"25","author":"Wan","year":"2024","journal-title":"Lancet Oncol"},{"key":"zoi250553r27","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.287215","article-title":"Teclistamab versus B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy in multiple myeloma: a comparative effectiveness analysis.","author":"Song","year":"2025","journal-title":"Haematologica"},{"issue":"6","key":"zoi250553r28","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaccao.2024.08.001","article-title":"SGLT2i and primary prevention of cancer therapy-related cardiac dysfunction in patients with diabetes.","volume":"6","author":"Bhatti","year":"2024","journal-title":"JACC CardioOncol"},{"issue":"8","key":"zoi250553r29","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1016\/j.jacep.2024.03.031","article-title":"Effects of glucagon-like peptide-1 receptor agonists on atrial fibrillation recurrence after catheter ablation.","volume":"10","author":"Satti","year":"2024","journal-title":"JACC Clin Electrophysiology"},{"issue":"10","key":"zoi250553r30","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.jacep.2023.06.008","article-title":"Impact of SGLT2 inhibitors on AF recurrence after catheter ablation in patients with type 2 diabetes.","volume":"9","author":"Abu-Qaoud","year":"2023","journal-title":"JACC Clin Electrophysiol"},{"issue":"5","key":"zoi250553r31","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jchf.2025.01.025","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors in Tafamidis-Treated Transthyretin Amyloid Cardiomyopathy: A Contemporary Real-World Analysis.","volume":"13","author":"Chi","year":"2025","journal-title":"JACC Heart Fail"},{"issue":"4","key":"zoi250553r32","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value.","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"issue":"12","key":"zoi250553r33","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1111\/dom.15226","article-title":"Cardiovascular prevention with glucose-lowering drugs in type 2 diabetes: an evidence-based approach to the categories of primary and secondary prevention.","volume":"25","author":"Mannucci","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"zoi250553r34","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1111\/bjh.16487","article-title":"The prevalence and significance of monoclonal gammopathy of undetermined significance in acute medical admissions.","volume":"189","author":"Atkin","year":"2020","journal-title":"Br J Haematol"},{"issue":"5","key":"zoi250553r35","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.","volume":"121","author":"International Myeloma Working Group","year":"2003","journal-title":"Br J Haematol"},{"issue":"6","key":"zoi250553r36","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1053\/j.ajkd.2003.08.040","article-title":"Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors.","volume":"42","author":"Pozzi","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"zoi250553r37","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1182\/bloodadvances.2023010843","article-title":"Mass spectrometry-detected MGUS is associated with obesity and other novel modifiable risk factors in a high-risk population.","volume":"8","author":"Lee","year":"2024","journal-title":"Blood Adv"},{"issue":"8","key":"zoi250553r38","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body fatness and cancer\u2014viewpoint of the IARC Working Group.","volume":"375","author":"Lauby-Secretan","year":"2016","journal-title":"N Engl J Med"},{"key":"zoi250553r39","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3389\/fendo.2016.00067","article-title":"Signaling interplay between bone marrow adipose tissue and multiple myeloma cells.","volume":"7","author":"Falank","year":"2016","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"zoi250553r40","doi-asserted-by":"publisher","first-page":"4358","DOI":"10.1158\/1538-7445.AM2023-4358","article-title":"Abstract 4358: glucagon-like peptide 1 agonist use and the progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus.","volume":"83","author":"Grandhi","year":"2023","journal-title":"Cancer Res"},{"key":"zoi250553r42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/ckj\/sfae296","article-title":"GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity.","volume":"17","author":"Abasheva","year":"2024","journal-title":"Clin Kidney J"},{"issue":"2","key":"zoi250553r43","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes.","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi250553r44","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity.","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi250553r45","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.jacc.2015.02.009","article-title":"Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations.","volume":"65","author":"Asgar","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"zoi250553r46","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jchf.2019.03.005","article-title":"Heart failure and atrial fibrillation, like fire and fury.","volume":"7","author":"Carlisle","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"3","key":"zoi250553r47","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jaccao.2022.07.002","article-title":"Cardiovascular associations with monoclonal gammopathy of undetermined significance: real or coincidental?","volume":"4","author":"Kapoor","year":"2022","journal-title":"JACC CardioOncol"},{"key":"zoi250553r41","unstructured":"Centers for Disease Control and Prevention. Chronic Kidney Disease Surveillance System. Accessed December 10, 2024. https:\/\/nccd.cdc.gov\/ckd\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2835801\/chi_2025_oi_250553_1750697080.62902.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T11:00:30Z","timestamp":1751281230000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2835801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.17541","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]}}}